Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
Patrick Kesslak, Martin Tolar(Alzheimer's Association), Susan Flint(Framingham State University), David Watson(Alzheimer’s Disease Neuroimaging Initiative), Jerome Barakos(Sutter Health), Aidan Power, Earvin Liang, Susan Abushakra(Framingham State University), Rosalind MacLaine(Framingham State University), Mercè Boada(Fundació ACE), Anton P. Porsteinsson(University of Rochester), Sharon Cohen(Toronto Public Health), John A. Hey(Framingham State University), Marwan N. Sabbagh(Barrow Neurological Institute), Emer MacSweeney(Cambridge Cognition (United Kingdom))
Cited by 0
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602